Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Abstract

Pharmaceutical compositions of the invention are presented which comprise substituted aminothiazoles derivatives. The substituted aminothiazoles derivatives have a disease-modifying action in the treatment of diseases associated with unregulated cell growth. Such diseases include cancers such as hepatocellular carcinoma, and viral infections from a hepatitis virus.

1 . A compound having formula (I): 
       
         
           
           
               
               
           
         
         Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: 
         R 1  is selected from the group consisting of hydrogen, C 1 -C 9  linear alkyl, isopropyl, cyclohexyl, bromine, cyano, 
       
       
         
           
           
               
               
           
         
         R 2  is selected from the group consisting of hydrogen, methyl, isopropyl, tert-butyl, benzyl, and 
       
       
         
           
           
               
               
           
         
         Ar 1  is selected from the group consisting of phenyl, 
       
       
         
           
           
               
               
           
         
         Ar 2  is selected from the group consisting of phenyl, 
       
       
         
           
           
               
               
           
         
       
       wherein compounds of the structures 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       are excluded from the compounds of formula (I). 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . The compound according to  claim 1 , which is:
 4-(pyridin-2-yl)-n-(pyrimidin-4-yl)thiazol-2-amine;   4-(6-bromopyridin-2-yl)-n-(pyrimidin-2-yl)thiazol-2-amine;   4-(4-methylpyridin-2-yl)-n-(pyrimidin-2-yl)thiazol-2-amine;   4-(3,5-dimethylpyridin-2-yl)-n-(pyrimidin-2-yl)thiazol-2-amine;   6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;   N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;   N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:   4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;   6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol- 2 -amine;   5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;   5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;   Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate ;   ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate ;   ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate ;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;   methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide   N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino) benzamido)-1,21-dioxo-1-(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20-diazapentacosan-25-oic acid;   N-(31-oxo-35-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino) thiazole-5-carboxamide;   4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile;   and pharmaceutically acceptable forms thereof.   
     
     
         7 . A composition comprising an effective amount of at least one compound according to  claim 1 . 
     
     
         8 . A composition according to  claim 7 , further comprising at least one excipient. 
     
     
         9 . A composition according to  claim 8 , wherein the at least one compound is at least one member selected from the group consisting of:
 4-(pyridin-2-yl)-N-(pyrimidin-4-yl)thiazol-2-amine;   4-(6-bromopyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(4-methylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(3,5-dimethylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;   N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;   N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:   4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;   6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol-2-amine;   5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;   5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;   Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5 -carboxylate;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;   Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-1,21-dioxo-1-(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20-diazapentacosan-25-oic acid;   N-(31-oxo-35-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3, 4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino) thiazole-5-carboxamide;   4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile and pharmaceutically acceptable forms thereof.   
     
     
         10 . (canceled) 
     
     
         11 . A method for treating a disease associated with unregulated cell growth, said method comprising administering to a subject an effective amount of at least one compound of the formula (I), 
       
         
           
           
               
               
           
         
       
       including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, to treat the disease wherein:
 R 1  is selected from the group consisting of hydrogen, C 1 -C 9  linear alkyl, isopropyl, cyclohexyl, bromine, cyano, 
 
       
         
           
           
               
               
           
         
         R 2  is selected from the group consisting of hydrogen, methyl, isopropyl, tert-butyl, benzyl, and 
       
       
         
           
           
               
               
           
         
         Ar 1  is selected from the group consisting of phenyl, 
       
       
         
           
           
               
               
           
         
         Ar  2  is selected from the group consisting of phenyl, 
       
       
         
           
           
               
               
           
         
       
     
     
         12 . (canceled) 
     
     
         13 . The method of  claim 11 , wherein the at least one compound is administered in a composition further comprising at least one excipient. 
     
     
         14 . The method of  claim 13 , wherein the at least one compound is at least one member selected from the group consisting of
 4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N,4-diphenylthiazol-2-amine;   N-phenyl-4-(pyridin-2-yl)thiazol-2-amine;   4-phenyl-N-(pyrimidin-2-yl)thiazol-2-amine;   N,4-di(pyridin-2-yl)thiazol-2-amine;   4-(pyridin-3-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(pyridin-4-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-(pyrazin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   4-(pyridin-2-yl)-N-(pyrimidin-4-yl)thiazol-2-amine;   4-(6-bromopyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(4-methylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(3,5-dimethylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;   N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;   N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:   4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;   6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol- 2 -amine;   5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;   5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;   Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;   Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-1,21-dioxo-1-(4- (pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20- diazapentacosan-25-oic acid;   N-(31-oxo-35-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3, 4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2- ylamino) thiazole-5-carboxamide;   4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile;   3-(4-Phenyl-thiazol-2-ylamino)-phenol;   (3-Chloro-2-methyl-phenyl)-(4-pyridin-2-yl-thiazol-2-yl)-amine;   and pharmaceutically acceptable forms thereof.   
     
     
         15 . The method of  claim 11 , wherein the disease associated with unregulated cell growth is a cancer selected from the group consisting of hepatocellular carcinoma, primary liver cancer, hepatoblastoma, breast cancer, ovarian cancer, lung cancer, leukemia and cholangiocarcinoma. 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . The method of  claim 11 , wherein the disease associated with unregulated cell growth is metastatic disease. 
     
     
         25 . A method for treating a disease associated with infection of the liver with a virus, said method comprising administering to a subject an effective amount of at least one compound of the formula (I), 
       
         
           
           
               
               
           
         
       
       including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, to treat the disease wherein:
 R 1  is selected from the group consisting of hydrogen, C 1 -C 9  linear alkyl, isopropyl, cyclohexyl, bromine, cyano, 
 
       
         
           
           
               
               
           
         
         R 2  is selected from the group consisting of hydrogen, methyl, isopropyl, tert-butyl, benzyl, and 
       
       
         
           
           
               
               
           
         
         Ar 1  is selected from the group consisting of phenyl, 
       
       
         
           
           
               
               
           
         
         Ar 2 is selected from the group consisting of phenyl, 
       
       
         
           
           
               
               
           
         
       
     
     
         26 . (canceled) 
     
     
         27 . The method of  claim 25 , wherein the at least one compound is administered in a composition further comprising at least one excipient. 
     
     
         28 . The method of  claim 27 , wherein the at least one compound is at least one member selected from the group consisting of
 4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N,4-diphenylthiazol-2-amine;   N-phenyl-4-(pyridin-2-yl)thiazol-2-amine;   4-phenyl-N-(pyrimidin-2-yl)thiazol-2-amine;   N,4-di(pyridin-2-yl)thiazol-2-amine;   4-(pyridin-3-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(pyridin-4-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-(pyrazin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   4-(pyridin-2-yl)-N-(pyrimidin-4-yl)thiazol-2-amine;   4-(6-bromopyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(4-methylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   4-(3,5-dimethylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;   N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;   N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;   N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:   4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;   6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol-2-amine;   5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;   5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;   (4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;   Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5 -carboxylate;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;   Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;   tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;   4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;   24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino) benzamido)-1,21-dioxo-1-(4- (pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20-diazapentacosan-25-oic acid;   N-(31-oxo-35-((3as,4s,6aR)-2-oxohexahydro-1H-thieno[3, 4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino) thiazole-5-carboxamide;   4-pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile;   3-(4-phenyl-thiazol-2-ylamino)-phenol;   (3-chloro-2-methyl-phenyl)-(4-pyridin-2-yl-thiazol-2-yl)-amine;   and pharmaceutically acceptable forms thereof.   
     
     
         29 . The method of  claim 25 , wherein the virus is a hepatitis virus. 
     
     
         30 . The method of  claim 25 , wherein the hepatitis virus is the hepatits A virus. 
     
     
         31 . The method of  claim 25 , wherein the hepatitis virus is the hepatits B virus. 
     
     
         32 . The method of  claim 25 , wherein the hepatitis virus is the hepatits C virus. 
     
     
         33 . The method of  claim 25 , wherein the hepatitis virus is the hepatits D virus. 
     
     
         34 . The method of  claim 25 , wherein the hepatitis virus is the hepatits E virus. 
     
     
         35 . The method of  claim 25 , wherein the virus is any virus infecting the liver